1887

Abstract

Despite the development of new vaccine formulations using new biotechnology resources to combat emerging and re-emerging diseases, serogroup B meningococcal disease is still a worldwide burden, accounting for many deaths and disabilities every year. The successful approach of coupling a polysaccharide (PS) with a carrier protein in order to increase long-lasting immunity could not be exploited against B because of the limitations of using the capsular PS of serogroup B meningococci. Tailor-made vaccines based on exposed proteins were shown to be a promising approach to overcome these flaws. However, the continuous adaptation of surface meningococcal structures to the external environment has led to genetic shifts of potential vaccine-target epitopes, hampering the quest for a broad-range vaccine that could be used against all serogroups, especially against serogroup B.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.011189-0
2009-09-01
2019-10-15
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/9/1127.html?itemId=/content/journal/jmm/10.1099/jmm.0.011189-0&mimeType=html&fmt=ahah

References

  1. Beernink, P. T., Leipus, A. & Granoff, D. M. ( 2006; ). Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 13, 758–763.[CrossRef]
    [Google Scholar]
  2. Beernink, P. T., Welsch, J. A., Harrison, L. H., Leipus, A., Kaplan, S. L. & Granoff, D. M. ( 2007; ). Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 195, 1472–1479.[CrossRef]
    [Google Scholar]
  3. Bernardini, G., Braconi, D., Martelli, P. & Santucci, A. ( 2007; ). Postgenomics of Neisseria meningitidis for vaccines development. Expert Rev Proteomics 4, 667–677.[CrossRef]
    [Google Scholar]
  4. Bisgard, K. M., Kao, A., Leake, J., Strebel, P. M., Perkins, B. A. & Wharton, M. ( 1998; ). Haemophilus influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis 4, 229–237.[CrossRef]
    [Google Scholar]
  5. Brandtzaeg, P. & Van Deuren, M. ( 2002; ). Current concepts in the role of the host response in Neisseria meningitidis septic shock. Curr Opin Infect Dis 15, 247–252.[CrossRef]
    [Google Scholar]
  6. Comanducci, M., Bambini, S., Caugant, D. A., Mora, M., Brunelli, B., Capecchi, B., Ciucchi, L., Rappuoli, R. & Pizza, M. ( 2004; ). NadA diversity and carriage in Neisseria meningitidis. Infect Immun 72, 4217–4223.[CrossRef]
    [Google Scholar]
  7. de Filippis, I., do Nascimento, C. R., Clementino, M. B. M., Sereno, A. B., Rebelo, C., Souza, N. N. & Riley, L. W. ( 2005; ). Rapid detection of Neisseria meningitidis in cerebrospinal fluid by one-step polymerase chain reaction of the nspA gene. Diagn Microbiol Infect Dis 51, 85–90.[CrossRef]
    [Google Scholar]
  8. Dyet, K. H. & Martin, D. R. ( 2005; ). Sequence variation in the porB gene from B : P1.4 meningococci causing New Zealand's epidemic. J Clin Microbiol 43, 838–842.[CrossRef]
    [Google Scholar]
  9. Feil, E. J., Maiden, M. C., Achtman, M. & Spratt, B. G. ( 1999; ). The relative contributions of recombination and mutation to the divergence of clones of Neisseria meningitidis. Mol Biol Evol 16, 1496–1502.[CrossRef]
    [Google Scholar]
  10. Frasch, C. E. ( 2005; ). Recent developments in Neisseria meningitidis group A conjugate vaccines. Expert Opin Biol Ther 5, 273–280.[CrossRef]
    [Google Scholar]
  11. Gardner, P. ( 2006; ). Clinical practice. Prevention of meningococcal disease. N Engl J Med 355, 1466–1473.[CrossRef]
    [Google Scholar]
  12. Giuliani, M. M., Santini, L., Brunelli, B., Biolchi, A., Aricò, B., Di Marcello, F., Cartocci, E., Comanducci, M., Masignani, V. & other authors ( 2005; ). The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun 73, 1151–1160.[CrossRef]
    [Google Scholar]
  13. Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A. & other authors ( 2006; ). A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 103, 10834–10839.[CrossRef]
    [Google Scholar]
  14. Granoff, D. M., Bartoloni, A., Ricci, S., Gallo, E., Rosa, D., Ravenscroft, N., Guarnieri, V., Seid, R. C., Shan, A. & other authors ( 1998; ). Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160, 5028–5036.
    [Google Scholar]
  15. Halperin, S. A., Langley, J. M., Smith, B., Wunderli, P., Kaufman, L., Kimura, A. & Martin, D. ( 2007; ). Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25, 450–457.[CrossRef]
    [Google Scholar]
  16. Hammitt, L. L., Block, S., Hennessy, T. W., Debyle, C., Peters, H., Parkinson, A., Singleton, R. & Butler, J. C. ( 2005; ). Outbreak of invasive Haemophilus influenzae serotype a disease. Pediatr Infect Dis J 24, 453–456.[CrossRef]
    [Google Scholar]
  17. Hodgson, A., Forgor, A. A., Chandramohan, D., Reed, Z., Binka, F., Bevilacqua, C., Boutriau, D. & Greenwood, B. ( 2008; ). A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS One 3, e2159 [CrossRef]
    [Google Scholar]
  18. Hou, V. C., Moe, G. R., Raad, Z., Wuorimaa, T. & Granoff, D. M. ( 2003; ). Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71, 6844–6849.[CrossRef]
    [Google Scholar]
  19. Jacobsson, S., Thulin, S., Mölling, P., Unemo, M., Comanducci, M., Rappuoli, R. & Olcén, P. ( 2006; ). Sequence constancies and variations in genes encoding three new meningococcal vaccine candidate antigens. Vaccine 24, 2161–2168.[CrossRef]
    [Google Scholar]
  20. Jódar, L., LaForce, F. M., Ceccarini, C., Aguado, T. & Granoff, D. M. ( 2003; ). Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361, 1902–1904.[CrossRef]
    [Google Scholar]
  21. Koeberling, O., Welsch, J. A. & Granoff, D. ( 2007; ). Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived neisserial antigen 1870. Vaccine 25, 1912–1920.[CrossRef]
    [Google Scholar]
  22. Koeberling, O., Seubert, A. & Granoff, D. M. ( 2008; ). Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198, 262–270.[CrossRef]
    [Google Scholar]
  23. Maiden, M. C., Malorny, B. & Achtman, M. ( 1996; ). A global gene pool in the neisseriae. Mol Microbiol 21, 1297–1298.[CrossRef]
    [Google Scholar]
  24. Martin, S. L., Borrow, R., Van Der Ley, P., Dawson, M., Fox, A. J. & Cartwright, K. A. ( 2000; ). Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 18, 2476–2481.[CrossRef]
    [Google Scholar]
  25. Mitka, M. ( 2005; ). New vaccine should ease meningitis fears. JAMA 293, 1433–1434.[CrossRef]
    [Google Scholar]
  26. Moe, G. R. & Granoff, D. M. ( 2001; ). Molecular mimetics of Neisseria meningitidis serogroup B polysaccharide. Int Rev Immunol 20, 201–220.[CrossRef]
    [Google Scholar]
  27. Moe, G. R., Zuno-Mitchell, P., Hammond, S. N. & Granoff, D. M. ( 2002; ). Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70, 6021–6031.[CrossRef]
    [Google Scholar]
  28. Morelli, G., Malorny, B., Müller, K., Seiler, A., Wang, J. F., del Valle, J. & Achtman, M. ( 1997; ). Clonal descent and microevolution of Neisseria meningitidis during 30 years of epidemic spread. Mol Microbiol 25, 1047–1064.[CrossRef]
    [Google Scholar]
  29. Morley, S. L. & Pollard, A. J. ( 2001; ). Vaccine prevention of meningococcal disease, coming soon? Vaccine 20, 666–687.[CrossRef]
    [Google Scholar]
  30. Norheim, G., Aase, A., Caugant, D. A., Høiby, E. A., Fritzsønn, E., Tangen, T., Kristiansen, P., Heggelund, U. & Rosenqvist, E. ( 2005; ). Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23, 3762–3774.[CrossRef]
    [Google Scholar]
  31. O'Dwyer, C. A., Reddin, K., Martin, D., Taylor, S. C., Gorringe, A. R., Hudson, M. J., Brodeur, B. R., Langford, P. R. & Kroll, J. S. ( 2004; ). Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun 72, 6511–6518.[CrossRef]
    [Google Scholar]
  32. Oliver, K. J., Reddin, K. M., Bracegirdle, P., Hudson, M. J., Borrow, R., Feavers, I. M., Robinson, A., Cartwright, K. & Gorringe, A. R. ( 2002; ). Neisseria lactamica protects against experimental meningococcal infection. Infect Immun 70, 3621–3626.[CrossRef]
    [Google Scholar]
  33. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S. & Martin, D. ( 2005; ). MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23, 2191–2196.[CrossRef]
    [Google Scholar]
  34. Perrett, K. P. & Pollard, A. J. ( 2005; ). Towards an improved serogroup B Neisseria meningitidis vaccine. Expert Opin Biol Ther 5, 1611–1625.[CrossRef]
    [Google Scholar]
  35. Rappuoli, R. ( 2000; ). Reverse vaccinology. Curr Opin Microbiol 3, 445–450.[CrossRef]
    [Google Scholar]
  36. Rosenstein, N. E., Perkins, B. A., Stephens, D. S., Popovic, T. & Hughes, J. M. ( 2001; ). Medical progress: meningococcal disease. N Engl J Med 344, 1378–1388.[CrossRef]
    [Google Scholar]
  37. Rouppe van der Voort, E. , Schuller, M., Holst, J., de Vries, P., Van der Ley, P., Van den Dobbelsteen, G. & Poolman, J. ( 2000; ). Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys. Vaccine 18, 1334–1343.[CrossRef]
    [Google Scholar]
  38. Sexton, K., Lennon, D., Oster, P., Crengle, S., Martin, D., Mulholland, K., Percival, T., Reid, S., Stewart, J. & O'Hallahan, J. ( 2004a; ). The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J 117, U1015
    [Google Scholar]
  39. Sexton, K., Lennon, D., Oster, P., Aaberge, I., Martin, D., Reid, S., Wong, S. & O'Hallahan, J. ( 2004b; ). Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J 117.1 p preceding U1027.
    [Google Scholar]
  40. Stephens, D. S., Greenwood, B. & Brandtzaeg, P. ( 2007; ). Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 369, 2196–2210.[CrossRef]
    [Google Scholar]
  41. Suker, J., Feavers, I. M., Corbel, M. J., Jones, C. & Bolgiano, B. ( 2004; ). Control and lot release of meningococcal group C conjugate vaccines. Expert Rev Vaccines 3, 533–540.[CrossRef]
    [Google Scholar]
  42. Thomas, M. ( 2004; ). Prevention of group B meningococcal disease by vaccination: a difficult task. N Z Med J 117, U1016
    [Google Scholar]
  43. Thompson, E. A., Feavers, I. M. & Maiden, M. C. ( 2003; ). Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149, 1849–1858.[CrossRef]
    [Google Scholar]
  44. Tiwana, H., Clow, K. J., Hall, C., Feavers, I. M. & Charalambous, B. M. ( 2005; ). The immunogenicity of a conformationally restricted peptide mimetic of meningococcal lipooligosaccharide. Scand J Immunol 62, 385–392.[CrossRef]
    [Google Scholar]
  45. Tsang, R. S. W., Sill, M. L., Skinner, S. J., Law, D. K. S., Zhou, J. & Wylie, J. ( 2007; ). Characterization of invasive Haemophilus influenzae disease in Manitoba, Canada, 2000–2006: invasive disease due to non-type B strains. Clin Infect Dis 44, 1611–1614.[CrossRef]
    [Google Scholar]
  46. Unkmeir, A., Kämmerer, U., Stade, A., Hübner, C., Haller, S., Kolb-Mäurer, A., Frosch, M. & Dietrich, G. ( 2002; ). Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 70, 2454–2462.[CrossRef]
    [Google Scholar]
  47. Urwin, R., Russell, J. E., Thompson, E. A., Holmes, E. C., Feavers, I. M. & Maiden, M. C. ( 2004; ). Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 72, 5955–5962.[CrossRef]
    [Google Scholar]
  48. Vermont, C. L. & Van den Dobbelsteen, G. P. ( 2003; ). Meningococcal serogroup B infections: a search for a broadly protective vaccine. Expert Rev Vaccines 2, 673–681.[CrossRef]
    [Google Scholar]
  49. Wedege, E., Bolstad, K., Aase, A., Herstad, T. K., McCallum, L., Rosenqvist, E., Oster, P. & Martin, D. ( 2007; ). Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 14, 830–838.[CrossRef]
    [Google Scholar]
  50. WHO ( 1998; ). Control of Epidemic Meningococcal Disease, WHO practical guidelines, 2nd edn, WHO/EMC/BAC/98.3. http://www.who.int/emc. Geneva: World Health Organization.
  51. Wyle, F. A., Artenstein, M. S., Brandt, B. L., Tramont, E. C., Kasper, D. L., Altieri, P. L., Berman, S. L. & Lowenthal, J. P. ( 1972; ). Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 126, 514–521.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.011189-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error